What did @deluciavitality actually say?
The central claim here is a big one: "The FDA has finally removed the black box warning on hormone therapy for menopause." She frames this as a long-overdue correction to 20-plus years of fear driven by "outdated studies and older women using synthetic hormones," and contrasts that history with what she calls "bioidentical person-adjusted therapies" used today. The conclusion is that hormones, "when done right at the right time with the right provider," support heart, brain, bones, metabolism, mood, and skin.
That's a lot of ground to cover in under a minute. Some of it is real. Some of it is a meaningful overstatement of what actually happened. And the bioidentical framing deserves particular scrutiny, because that word is doing a lot of heavy lifting in ways that can mislead patients.
Does the science back this up?
Partially, but the FDA update is more complicated than a clean removal of a black box warning. The science on hormone therapy timing, however, is genuinely strong and has been for years.
In 2022, the FDA updated labeling for menopausal hormone therapy products to better reflect the "timing hypothesis," sometimes called the "window of opportunity." Research from the Women's Health Initiative Memory Study (Shumaker et al., 2003, JAMA) and subsequent re-analyses, including Manson et al. (2013, JAMA Internal Medicine), showed that women who began hormone therapy within 10 years of menopause or under age 60 had meaningfully different cardiovascular and cognitive risk profiles than older women who started later. The Kronos Early Estrogen Prevention Study (Harman et al., 2014, American Journal of Medicine) added to this body of evidence. So yes, timing matters enormously, and the original WHI findings were misapplied to younger, recently menopausal women for decades. That's real, and critics of the black box warning have had a legitimate case for years. The FDA labeling update, though, did not erase the black box. It revised context. That distinction matters.
What did they get wrong (or right)?
They got the historical critique mostly right. The original WHI study enrolled women with a mean age of 63, and applying those results to 50-year-olds going through perimenopause was always a stretch. Millions of women were undertreated because of that misapplication. That's a documented, widely acknowledged problem in women's health. Credit where it's due.
What's misleading is the "bioidentical" framing. The claim that "bioidentical person-adjusted therapies" are categorically safer than the synthetic hormones studied in the WHI is not established by regulatory science. The FDA does not recognize "bioidentical" as a clinical or safety classification. Compounded bioidentical hormones, in particular, lack the clinical trial data that FDA-approved estradiol and progesterone products carry. The Endocrine Society's 2016 scientific statement was explicit: there is no evidence that compounded bioidentical hormones are safer or more effective than approved therapies. Calling compounded products superior to FDA-approved ones is not something the evidence supports, and it can steer patients toward less-tested options.
The claim that hormones support "your heart, your brain, your bones, your metabolism, your mood, your skin, everything" is a broad sweep. Bone protection is well-supported (Cauley et al., 2003, JAMA). Cardiovascular effects remain timing-dependent and nuanced. Cognitive protection is still under active investigation.
What should you actually know?
The FDA did update menopausal hormone therapy labeling in recent years to better reflect timing-dependent risk, and the medical community has been moving toward a more individualized, less fear-based approach to HRT for over a decade. That shift is real and evidence-based. Organizations like the Menopause Society (formerly NAMS) support hormone therapy as appropriate first-line treatment for symptomatic women under 60 who are within 10 years of menopause onset, without contraindications.
But "the FDA removed the black box warning" is not precisely accurate as stated. The boxed warning on systemic estrogen products still exists in updated form. The framing of bioidentical compounded hormones as a distinct, safer category is not supported by current regulatory science. Patients should know:
- FDA-approved estradiol and micronized progesterone have clinical trial data behind them. Compounded preparations do not carry equivalent evidence.
- The timing hypothesis is real and clinically important, but it applies to FDA-approved therapies too, not just compounded ones.
- Any provider claiming that a compounded hormone is safer than its FDA-approved counterpart should be asked for the specific evidence behind that claim.
- If you are considering hormone therapy, a board-certified menopause specialist or your OB-GYN is the right starting point, not an Instagram video.